PRKCD
Protein kinase C delta type
As of the edition of 20 October 2026, PRKCD (protein kinase C delta type, UniProt Q05655) has 2 drugs tested at it and 3 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q05655
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 2
- Disease areas
- Cancer; Skin and connective tissue; Infections; Heart and blood vessels; Urinary and reproductive
- Registered trials of its drugs
- 55
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ingenol mebutate | Marketed | Phase 4 | none listed |
| Delcasertib | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| LEO Pharma | Route B |
| Amgen | Route A |
The other 1 company at PRKCD
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at PRKCD, ranked, with the facts behind eachRequest access. Nothing is shown until you do.